Kestra Medical Technologies, Ltd. Cost of Revenue
Kestra Medical Technologies, Ltd. (KMTS) reported Cost of Revenue of $13.47 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-09-14
- Kestra Medical Technologies, Ltd. cost of goods and services sold for the quarter ending 2026-07-31 was $13.47M, a 28.07% increase year-over-year.
- Kestra Medical Technologies, Ltd. cost of goods and services sold for the quarter ending 2026-04-30 was $12.96M, a 34.96% increase year-over-year.
- Kestra Medical Technologies, Ltd. cost of goods and services sold for the quarter ending 2026-01-31 was $11.65M, a 36.32% increase year-over-year.
- Kestra Medical Technologies, Ltd. cost of goods and services sold for the quarter ending 2025-10-31 was $11.14M, a 25.46% increase year-over-year.
- Kestra Medical Technologies, Ltd. cost of goods and services sold for fiscal 2026 was $46.26M, a 29.93% increase from fiscal 2025.
- Kestra Medical Technologies, Ltd. cost of goods and services sold for fiscal 2025 was $35.60M, a 29.70% increase from fiscal 2024.
- Kestra Medical Technologies, Ltd. cost of goods and services sold for fiscal 2024 was $27.45M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-07-31 | $13.47M 10-Q · filed 2026-09-14 | $26.43M derived: sum of 2 quarters · filed 2026-09-14 | $38.08M derived: sum of 3 quarters · filed 2026-09-14 | $49.22M derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $12.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $24.60M derived: sum of 2 quarters · filed 2026-07-14 | $35.74M derived: sum of 3 quarters · filed 2026-07-14 | $46.26M 10-K · filed 2026-07-14 |
| 2026-01-31 | $11.65M 10-Q · filed 2026-03-17 | $22.79M derived: sum of 2 quarters · filed 2026-03-17 | $33.31M 10-Q · filed 2026-03-17 | $42.91M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $11.14M 10-Q · filed 2025-12-11 | $21.66M 10-Q · filed 2025-12-11 | $31.26M derived: sum of 3 quarters · filed 2026-09-14 | $39.80M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $10.52M 10-Q · filed 2026-09-14 | $20.12M derived: sum of 2 quarters · filed 2026-09-14 | $28.66M derived: sum of 3 quarters · filed 2026-09-14 | $37.54M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $18.14M derived: sum of 2 quarters · filed 2026-07-14 | $27.02M derived: sum of 3 quarters · filed 2026-07-14 | $35.60M 10-K · filed 2026-07-14 |
| 2025-01-31 | $8.54M 10-Q · filed 2026-03-17 | $17.42M derived: sum of 2 quarters · filed 2026-03-17 | $26.00M 10-Q · filed 2026-03-17 | |
| 2024-10-31 | $8.88M 10-Q · filed 2025-12-11 | $17.46M 10-Q · filed 2025-12-11 | ||
| 2024-07-31 | $8.58M 10-Q · filed 2025-09-12 | |||
| 2024-04-30 | $27.45M 10-K · filed 2025-07-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |